We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non‐renal solid organ transplant recipients?
- Authors
Gatti, Milo; Rinaldi, Matteo; Potena, Luciano; Salvaterra, Elena; Morelli, Maria Cristina; Giannella, Maddalena; Viale, Pierluigi; Pea, Federico
- Abstract
Objectives: The aim of this study is to explore the relationship between ganciclovir exposure and clinical efficacy and/or safety in non‐renal solid organ transplant (SOT) recipients receiving preemptive therapy with ganciclovir/valganciclovir and undergoing therapeutic drug monitoring (TDM)‐guided dosing optimization. Methods: Non‐renal SOT recipients admitted to IRCCS Azienda Ospedaliero‐Universitaria of Bologna receiving preemptive therapy with ganciclovir or valganciclovir for active cytomegalovirus (CMV) infection and who underwent at least one TDM were included. Desired ganciclovir Cmin range was set at 1–3 mg/L, and average ganciclovir trough concentrations (Cmin) were calculated for each patient. Reduced CMV viral load below the lower limit of quantification (LLQ) at 30 days and occurrence of myelotoxicity were selected as the primary outcome. Univariate analysis was performed by comparing patients with average Cmin below or above 1 or 3 mg/L. Receiver operating characteristic (ROC) curve analysis was performed to identify the average ganciclovir Cmin cut‐off predictive for clinical efficacy or toxicity. Results: Twenty‐nine out of 89 retrieved patients met the inclusion criteria, with a median (interquartile [IQR]) baseline CMV viral load of 27,163 copies/mL (IQR 13 159.75–151 340.25 copies/mL). Reduced CMV viral load below the LLQ at 30 days was found in 17 patients (58.6%). No difference was found in the primary outcome between patients showing average Cmin below or above 1 mg/L (100.0% vs. 53.8%; p =.25) and/or 3 mg/L (65.2% vs. 33.3%; p =.20). ROC analysis did not allow to identify an average Cmin cut‐off predictive of clinical efficacy or toxicity. Conclusions: No clear relationship between ganciclovir Cmin and neither CMV eradication nor safety issues was identified.
- Subjects
BOLOGNA (Italy); DRUG monitoring; CYTOMEGALOVIRUS diseases; TRANSPLANTATION of organs, tissues, etc.; GANCICLOVIR; RECEIVER operating characteristic curves
- Publication
Transplant Infectious Disease, 2023, Vol 25, Issue 5, p1
- ISSN
1398-2273
- Publication type
Article
- DOI
10.1111/tid.14107